Kingdon Capital Management’s Biogen BIIB Stock Holding History

Kingdon Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-94,000	Closed	-$22.6M	–	89
2021 Q4	$22.6M	Buy	+94,000	New	+$24.2M	2.59%	10

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Kingdon Capital Management's BIIB Position: Q2 2018 in Review

Kingdon Capital Management sold out of Biogen (BIIB) in Q2 2018, closing a stake of 10,076 shares — an estimated $2.76M sold.

Kingdon Capital Management first reported a position in BIIB in Q1 2015 and held it in 2 quarters. The position peaked at $2.76M in Q1 2018. 1,098 funds tracked by Wall St. Rank hold BIIB as of Q2 2018.

Kingdon Capital Management reported no remaining Biogen position as of Q2 2018 after selling out during the quarter.
Kingdon Capital Management sold 10,076 Biogen shares in Q2 2018, an estimated $2.76M.
Kingdon Capital Management first reported a position in Biogen in Q1 2015 and held it in 2 quarters.
Kingdon Capital Management's Biogen position peaked at $2.76M in Q1 2018.
1,098 funds tracked by Wall St. Rank held Biogen as of Q2 2018.

Based on Kingdon Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.